Vir Biotechnology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-04-07
- Employees
- 587
- Market Cap
- -
- Website
- http://www.vir.bio
- Introduction
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Solid Tumor MalignanciesEGFR Positive Solid TumorsEGFR
- Interventions
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT06960395
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇦🇺Wollongong Hospital, Wollongong, New South Wales, Australia
🇦🇺Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06903338
- Locations
- 🇺🇦
Investigative Site, Kyiv, Ukraine
To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV
- Conditions
- HIV I Infection
- Interventions
- Biological: Placebo
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT05854381
- Locations
- 🇿🇦
Setshaba Research Centre CRS, Soshanguve, Gauteng, South Africa
🇺🇸Alabama CRS, Birmingham, Alabama, United States
🇺🇸The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States
A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05844228
- Locations
- 🇺🇸
Inland Empire Clinical Trials, Rialto, California, United States
🇺🇸Floridian Clinical Research, Miami Lakes, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study to Evaluate Investigational Therapies in Chronic Hepatitis B Virus Infection
- Conditions
- Chronic Hepatitis B Virus (HBV) Infection
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Vir Biotechnology Inc.
- Target Recruit Count
- 13
- Registration Number
- 2024-513176-17-00
- Locations
- 🇫🇷
Hopital Beaujon, Clichy, France
🇷🇴Institutul National De Boli Infectioase Prof.Dr.Matei Bals, Bucharest, Romania
A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A
- Conditions
- Influenza A
- Interventions
- Biological: VIR-2482 (450 mg)Biological: VIR-2482 (1200 mg)Biological: Placebo
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 2985
- Registration Number
- NCT05567783
- Locations
- 🇺🇸
Investigative Site, Norfolk, Virginia, United States
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT05484206
- Locations
- 🇺🇸
Inland Empire Clinical Trials, Rialto, California, United States
🇺🇸Orange County Research Center, Tustin, California, United States
🇺🇸CenExel Research Centers of America, Hollywood, Florida, United States
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT05461170
- Locations
- 🇬🇧
Investigative Site, Manchester, United Kingdom
Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 504
- Registration Number
- NCT05280717
- Locations
- 🇺🇸
Investigative Site, West Jordan, Utah, United States
Sotrovimab Expanded Access Treatment Protocol (COVID-19)
- Conditions
- Covid19
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- Vir Biotechnology, Inc.
- Registration Number
- NCT05235347
- Locations
- 🇺🇸
Site, Seattle, Washington, United States